Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Recombinant Human Erythropoietin on Patient Survival Rate during Severe Sepsis
TCTR20201022004Recruiting
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of erythropoietin in sepsis, sponsored by None. Primary endpoint: Patient survival rate during severe sepsis. Started Jun 2020; status: recruiting.
02
Drugs
erythropoietin
03
Conditions
sepsis
Beyond the preview
Go deeper on TCTR20201022004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201022004.